GlobeNewswire·Jul 16, 2026, 4:05 PM ET

Gyre Therapeutics Appoints Three New Members to its Board of Directors

GYRE

Gyre Therapeutics, Inc. (NASDAQ: GYRE) appointed three new Board members effective August 1, 2026: Yue Xiong, Ph.D., Maxwell Kirkby, and Claire Weston, Ph.D.
Dr. Xiong, the Company's Chief Scientific Officer since May 2026, will serve as a Class I director with a term expiring at the 2028 annual meeting.
Maxwell Kirkby will serve as a Class II director with a term expiring at the 2029 annual meeting and was appointed to the Compensation Committee.
Dr. Weston will serve as a Class III director with a term expiring at the 2027 annual meeting and was appointed to the Audit Committee.
The Board expanded its expertise in scientific leadership, clinical development, cross-border operations, governance, and life sciences scaling to support Gyre's pipeline targeting fibrosis, cancer, inflammation, and pain.
Dr. Xiong previously led the Cancer Cell Biology Program at UNC Lineberger, held a William R. Kenan Professorship, published over 200 research articles, holds two U.S. patents, and was elected an AAAS Fellow in 2012.
Mr. Kirkby brings decades of cross-border drug development experience, having previously held leadership roles at Bristol-Myers Squibb, Amgen, and AstraZeneca in China, Japan, and Asia Pacific.
Dr. Weston is the Founder CEO of Tactus AI LLC since January 2025, previously founded Reveal Biosciences Inc., holds a Ph.D. in Cell Biology from the University of Cambridge, and served as Chair of the Board for Reveal Biosciences.
Gyre Pharmaceuticals, a subsidiary with 69.7% equity ownership as of March 31, 2026, markets ETUARY™ for IPF in the PRC and has an NDA under review for F351 to treat CHB-induced liver fibrosis.
Gyre Therapeutics focuses on small-molecule therapeutics for organ fibrosis and inflammatory diseases, while its subsidiary Cullgen Inc. develops targeted protein degraders and degrader-antibody conjugates for cancer and inflammation.